lapatinib has been researched along with sirolimus in 35 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | lapatinib (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (28.57) | 29.6817 |
| 2010's | 23 (65.71) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Egbert, M; Keserű, GM; Vajda, S; Whitty, A | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Civiello, G; Janne, PA; Johnson, BE; Mukohara, T | 1 |
| Hampton, T | 1 |
| Bankhead, C | 1 |
| Elstner, E; Emde, A; Eucker, J; Kühnl, A; Liu, H; Planas-Silva, MD; Possinger, K; Rosche, M; Schulz, CO; Zang, C | 1 |
| Fricker, J | 1 |
| Hortobagyi, GN; Pusztai, L; Ravdin, PM; Ross, JS; Slodkowska, EA; Symmans, WF | 1 |
| Abbara, C; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Gonin, P; Noël-Hudson, MS; Thomas-Bourgneuf, L | 1 |
| Hede, K | 1 |
| Akhavan, D; Bensinger, SJ; Cloughesy, TF; Dang, J; DeAngelis, LM; Guo, D; Hock, MB; Horvath, S; Huang, TT; Iwanami, A; Kofman, AA; Kuga, D; Kuhn, JG; Lin, KY; Mehta, MP; Mellinghoff, IK; Mischel, PS; Prados, MD; Prins, RM; Robins, HI; Soto, H; Vinters, HV; Watson, AD; Wen, PY; Yong, WH; Zhu, S | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hilfrich, J; Kreienberg, R; Loibl, S; Nekljudova, V; Solbach, C; Strumberg, D; Untch, M; von Minckwitz, G | 1 |
| Korman, DB | 1 |
| Adams, A; Dolan, R; Graham, TR; Liu, T; Lobo, C; O'Regan, RM; Sun, SY; Taliaferro-Smith, LD; Tighiouart, M; Yacoub, R; Yang, L | 1 |
| de Azambuja, E; Metzger-Filho, O | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Bigot, L; Boige, V; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Goéré, D; Gonin, P; Marion, S; Noël-Hudson, MS; Polrot, M | 1 |
| Ito, Y | 1 |
| Chekaluk, Y; Du, J; Gray, NS; Guo, Y; Kwiatkowski, DJ; Wu, CL; Zhang, J | 1 |
| Christensen, SD; Chung, V; Gadgeel, SM; Hoering, A; Kingsbury, L; Kurzrock, R; Lew, DL; LoRusso, P; Smith, DC; Synold, TW | 1 |
| Kümler, I; Nielsen, DL; Tuxen, MK | 1 |
| Gyõrffy, B; Mihály, Z | 1 |
| Barroso-Sousa, R; de Melo Gagliato, D; Mano, MS; Santana, IA; Testa, L | 1 |
| Mehta, A; Tripathy, D | 1 |
| Blancafort, A; Brugada, R; Campuzano, Ò; Carrión-Salip, D; Giró-Perafita, A; Gómez-Miragaya, J; González-Suárez, E; Massaguer, A; Oliveras, G; Palafox, M; Palomeras, S; Puig, T; Turrado, C | 1 |
| Amin, DN; Gulizia, N; Moasser, MM; Ruiz-Saenz, A | 1 |
| Mehra, R; Zibelman, M | 1 |
| Borger, D; Chisholm, S; Foster, R; Growdon, WB; Hernandez, SF; Rueda, BR | 1 |
| Bittner, ML; Chao, S; Datta, A; Hua, J; Katiyar, A; Lopes, R; Mohanty, A | 1 |
10 review(s) available for lapatinib and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Evidence-Based Medicine; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Lapatinib; Neoplasm Staging; Polymerase Chain Reaction; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Sirolimus; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Up-Regulation | 2009 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
A systematic review of dual targeting in HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Up-Regulation | 2014 |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Biological therapies in breast cancer: common toxicities and management strategies.
Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Humans; Immunosuppressive Agents; Lapatinib; Maytansine; Quinazolines; Sirolimus; Trastuzumab | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
1 trial(s) available for lapatinib and sirolimus
| Article | Year |
|---|---|
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Everolimus; Female; Humans; Incidence; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; United States; Young Adult | 2013 |
24 other study(ies) available for lapatinib and sirolimus
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Why Some Targets Benefit from beyond Rule of Five Drugs.
Topics: Binding Sites; Drug Discovery; Ligands; Molecular Weight; Protein Binding | 2019 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
Topics: Antibiotics, Antineoplastic; Butadienes; Cell Cycle; Chromones; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mesothelioma; Mitogen-Activated Protein Kinase 3; Morpholines; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pleural Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Sirolimus; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2006 |
Three new drugs available to fight kidney cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lapatinib; Multicenter Studies as Topic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
New hope for RCC patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lapatinib; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2006 |
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lignans; Magnolia; Medicine, Chinese Traditional; Quinazolines; Signal Transduction; Sirolimus; Time Factors | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Blotting, Western; Digoxin; Everolimus; Female; Intestinal Mucosa; Intestines; Lapatinib; Mice; Mice, Knockout; Quinazolines; Sirolimus; Substrate Specificity; Tissue Distribution | 2009 |
Gastric cancer: trastuzumab trial results spur search for other targets.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Everolimus; HSP90 Heat-Shock Proteins; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Receptor, ErbB-2; Sirolimus; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2009 |
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Fatty Acids; Gene Knockdown Techniques; Glioblastoma; Humans; Hydrolysis; Lapatinib; Lipogenesis; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Sterol Regulatory Element Binding Protein 1 | 2009 |
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Everolimus; Female; Humans; Lapatinib; Quinazolines; Sirolimus | 2011 |
[Breast cancer therapy with combination of endocrine and target drugs].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Sirolimus; Trastuzumab | 2011 |
Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Colorectal Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Mice; Mice, Nude; Mutation; Quinazolines; ras Proteins; Sirolimus; Xenograft Model Antitumor Assays | 2013 |
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Topics: Afatinib; Antibiotics, Antineoplastic; Cell Line, Tumor; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Loss of Heterozygosity; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; Resorcinols; Signal Transduction; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Catechin; Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acid Synthase, Type I; Female; Gallic Acid; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Naphthalenes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus; Trastuzumab | 2015 |
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Indoles; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Cell Cycle; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Cystadenoma, Serous; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2016 |
A Bayesian approach to determine the composition of heterogeneous cancer tissue.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Cell Count; Cell Line, Tumor; Computer Simulation; Humans; Lapatinib; Neoplasms; Probability; Sirolimus | 2018 |